Table 3.

In-hospital outcomes for propensity-matched study groups

Variable	HCQ-AZM group (N = 173)	Matched-control group (N = 173)	p value
Death	26 (15.0%)	18 (10.4%)	0.2
PEA arrest	13 (7.5%)	8 (4.8%)	0.43
Duration of hospitalization stay (days)	10.5 ± 7.4	5.8 ± 6.1	< 0.001
Tachyarrhythmia	18 (10.4%)	12 (6.9%)	0.28
Atrial fibrillation	9 (5.2%)	6 (3.4%)	0.23
SVT	5 (2.8%)	2 (1.2%)	0.22
VT	5 (2.8%)	3 (1.7%)	0.52
VF	0 (0%)	0 (0%)	1.0
Severe bradyarrhythmia	10 (5.7%)	6 (3.4%)	0.68
Sinus bradycardia	6 (3.5%)	5 (2.9%)	0.62
Pause	5 (2.8%)	2 (1.2%)	0.28
AV block	5 (3%)	3 (1.7%)	0.51

Note Some patients with Tachyarrhythmia and Bradyarrhythmia had more than one type of arrhythmia event

HCQ-AZM hydrochloroquine and azithromycin, PEA indicates pulseless electrical activity, SVT supraventricular arrhythmia, VT ventricular tachycardia (sustained), VF ventricular fibrillation, AV atrioventricular, HCQ hydroxychloroquine